Probing dopamine D2 receptor trafficking in schizophrenia
Probing dopamine D2 receptor trafficking in schizophrenia
批准号:
8584066
负责人:
Anissa Abi-Dargham
金额:
$25.49万
依托单位国家:
美国
项目类别:
财政年份:
2013
资助国家:
美国
项目状态:
已结题
起止时间:
2013-08-02 至 2015-06-30
关键词:
AccountingAcuteAdoptedAffinityAgonistAmphetaminesAntipsychotic AgentsAutopsyBindingCardiovascular systemCell Surface ReceptorsCell surfaceCellsClinical ResearchCorpus striatum structureCytosolDiseaseDopamineDopamine D2 ReceptorExposure toFelis catusFigs - dietaryFunctional disorderGoalsHourHumanHyperactive behaviorImageMeasuresMolecular GeneticsMonkeysPatientsPhasePlasmaPlayPopulationPositron-Emission TomographyProcessRacloprideReceptor CellReceptor SignalingRegulationRelative (related person)ResearchRodentRoleScanningSchizophreniaSolidSymptomsTestingabsorptionhealthy volunteerinsightmouse modelneuroimagingnonhuman primatenovelpublic health relevanceradioligandradiotracerreceptorreceptor densityreceptor internalizationtraffickingtransmission process
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): A large body of work has focused on excess dopamine within striatum of patients with schizophrenia but we know little about the underlying mechanistic involvement of dopamine D2 receptors (D2R) in the illness. Some imaging and postmortem studies have suggested that D2R density is elevated in patients with schizophrenia compared to healthy controls, however, these findings have not been consistent and it was argued that they may be more related to prior exposure to antipsychotics rather than to the disease process per se. Nevertheless, the alleviation of positive symptoms specifically after blockade of D2R by antipsychotics suggests that homeostatic regulation of
D2R signaling is likely to be compromised. One mechanism that may explain this is impaired internalization. D2R internalization is a mechanism that enables the cell to retract the receptors from the cell surface into the cytosol so they are no longer available for dopamine stimulation. Recent research, including genetic, molecular and postmortem studies, suggests that D2R internalization may be impaired in schizophrenia. These findings now call for further clinical studies of the role of D2R trafficking in schizophrenia. PET imaging combined with amphetamine challenge may offer a way to study D2R trafficking in humans. PET imaging has been commonly used to assess dopamine transmission by measuring the change in binding potential ( BPND) of a D2R radiotracer after an amphetamine challenge. BPND is thought to reflect direct displacement of the radiotracer due to increased competition from endogenous dopamine. However, some observations have suggested that the displacement is not only related to increased competition from dopamine, but also to internalization of the D2Rs. This was initially suggested by the observation that BPND remains decreased several hours after the amphetamine induced dopamine surge. This "late phase" decrease (e4 hr after amphetamine) in BPND has been observed across species including rodents, cats, monkeys and humans. Tests of a wide range of D2R radiotracers found on average about two-fold lower affinity for internalized D2R than cell surface bound, a change sufficient to explain the "late phase" decrease in BPND after amphetamine challenge. Consistent with this idea, a PET study in a mouse model deficient in D2R internalization failed to observe the "late phase" effect, suggesting that this imaging paradigm may provide information about D2R internalization. The goal of this proposal is to explore the hypothesis that impaired D2R trafficking plays a critical role in the dopaminergic abnormalities in schizophrenia. We propose to image 15 patients with schizophrenia and 15 healthy controls with PET, [11C]raclopride, at baseline, 3 h, and 8 h after amphetamine challenge (0.5 mg/kg, PO). We hypothesize that the "late phase" decrease in BPND will be blunted in patients with schizophrenia, reflecting impaired D2R trafficking in schizophrenia, most likely related to impaired D2R internalization. If successful, this lin of research may provide novel insight to the pathophysiology of schizophrenia.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Deep rTMS modulating insula synaptic density and smoking behavior in schizophrenia
-
批准号:10710181
-
项目类别:
-
资助金额:$35.86万
-
财政年份:2022
-
负责人:Anissa Abi-Dargham
-
依托单位:
Deep rTMS modulating insula synaptic density and smoking behavior in schizophrenia
-
批准号:10494515
-
项目类别:
-
资助金额:$35.86万
-
财政年份:2022
-
负责人:Anissa Abi-Dargham
-
依托单位:
Preliminary imaging studies of the kappa opioid receptors in schizophrenia and their relationship to dopamine function
-
批准号:10304170
-
项目类别:
-
资助金额:$19.94万
-
财政年份:2020
-
负责人:Anissa Abi-Dargham
-
依托单位:
Neurobiological correlates of auditory processing in health and disease: an RDoC study
-
批准号:9080754
-
项目类别:
-
资助金额:$73.25万
-
财政年份:2016
-
负责人:Anissa Abi-Dargham
-
依托单位:
Probing dopamine D2 receptor trafficking in schizophrenia
-
批准号:8712557
-
项目类别:
-
资助金额:$20.0万
-
财政年份:2013
-
负责人:Anissa Abi-Dargham
-
依托单位:
RC2 Alcohol-induced human striatal dopamine release related to alcoholism vulnera
-
批准号:8128248
-
项目类别:
-
资助金额:$25.46万
-
财政年份:2011
-
负责人:Anissa Abi-Dargham
-
依托单位:
Dopamine Dysfunction in Schizophrenia
-
批准号:8102708
-
项目类别:
-
资助金额:$193.6万
-
财政年份:2010
-
负责人:Anissa Abi-Dargham
-
依托单位:
Dopamine Dysfunction in Schizophrenia
-
批准号:8448257
-
项目类别:
-
资助金额:$177.26万
-
财政年份:2010
-
负责人:Anissa Abi-Dargham
-
依托单位:
Dopamine Dysfunction in Schizophrenia
-
批准号:7940012
-
项目类别:
-
资助金额:$199.85万
-
财政年份:2010
-
负责人:Anissa Abi-Dargham
-
依托单位:
Dopamine Dysfunction in Schizophrenia
-
批准号:8249495
-
项目类别:
-
资助金额:$188.94万
-
财政年份:2010
-
负责人:Anissa Abi-Dargham
-
依托单位:
Dopamine Dysfunction in Schizophrenia
-
批准号:8650332
-
项目类别:
-
资助金额:$180.53万
-
财政年份:2010
-
负责人:Anissa Abi-Dargham
-
依托单位:
Cortical and Striatal Dopamine Dysfunction in Addiction and Schizophrenia
-
批准号:7738569
-
项目类别:
-
资助金额:$12.37万
-
财政年份:2009
-
负责人:Anissa Abi-Dargham
-
依托单位:
Cortical and Striatal Dopamine Dysfunction in Addiction and Schizophrenia
-
批准号:7924734
-
项目类别:
-
资助金额:$12.37万
-
财政年份:2009
-
负责人:Anissa Abi-Dargham
-
依托单位:
Cortical and Striatal Dopamine Dysfunction in Addiction and Schizophrenia
-
批准号:8131905
-
项目类别:
-
资助金额:$12.37万
-
财政年份:2009
-
负责人:Anissa Abi-Dargham
-
依托单位:
Cortical and Striatal Dopamine Dysfunction in Addiction and Schizophrenia
-
批准号:8534844
-
项目类别:
-
资助金额:$12.37万
-
财政年份:2009
-
负责人:Anissa Abi-Dargham
-
依托单位:
Cortical and Striatal Dopamine Dysfunction in Addiction and Schizophrenia
-
批准号:8318271
-
项目类别:
-
资助金额:$12.37万
-
财政年份:2009
-
负责人:Anissa Abi-Dargham
-
依托单位:
Imaging dopamine transmission in comorbid schizophrenia and cannabis dependence
-
批准号:7384577
-
项目类别:
-
资助金额:$18.65万
-
财政年份:2008
-
负责人:Anissa Abi-Dargham
-
依托单位:
Imaging dopamine transmission in comorbid schizophrenia and cannabis dependence
-
批准号:7568789
-
项目类别:
-
资助金额:$16.26万
-
财政年份:2008
-
负责人:Anissa Abi-Dargham
-
依托单位:
Imaging dopamine transmission in cannabis dependence
-
批准号:7759602
-
项目类别:
-
资助金额:$38.91万
-
财政年份:2007
-
负责人:Anissa Abi-Dargham
-
依托单位:
CORE--CLINICAL
-
批准号:7457815
-
项目类别:
-
资助金额:$8.86万
-
财政年份:2007
-
负责人:Anissa Abi-Dargham
-
依托单位:
海外基金